Next Generation Sequencing (NGS) in lung cancer bio-marker testing can cut screening-time, according to research by Cancer Genetic Inc. (CCI).
In a presentation to delegates at the Association for Molecular Pathology (AMP) Annual Meeting, CGI’s Medical Director Dr.Daniel Duncan (pictured) explained how NGS can simplify the current algorithm testing of Non-small Cell Lung Cancer (NCSLC).
Minimum tissue requirements mean patients can be screened quickly for potential precision medicine therapies, a process assisted by CGI’s work with Thermo Fisher’s Oncome DX Target Test, a NGS-based companion diagnostic NCSLC, a technology launched in the United States this year. The results of the collaboration were presented for the first-time at the event in Salt Lake City, Utah today (15 November).
In a statement before the event, Dr.Duncan explained the importance of swift screening for those with NCSL. “For patients with lung cancer, days matter. Clinicians needs tests that provide fast turnaround times, requiring simplify workflows to meet these demands,” he said. “We’ve found the Oncomine Dx Target Test allows us to analyse NSCLC biomarkers using limited tumour sample to get results in days.”